A leading hypothesis proposed to explain these safety findings was that functional erythropoietin receptors (EPORs) are expressed in tumor cells and/or endothelial cells, allowing ESAs to directly stimulate tumor growth and/or counteract tumor-ablative therapies. This evidence concerns the gene EPOR and neoplasm.